Specify a stock or a cryptocurrency in the search bar to get a summary
Oculis Holding AG Ordinary shares
OCSOculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. Address: Bahnhofstrasse 7, Zug, Switzerland, 6300
Analytics
WallStreet Target Price
28.47 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OCS
Dividend Analytics OCS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OCS
Stock Valuation OCS
Financials OCS
Results | 2019 | Dynamics |